http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 06:37:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/Press+Releases/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <b><span value="ACORN:5021693578" idsrc="xmltag.org" >Insilico Medicine</span> (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company</b>, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of <money>US$106.3 million</money> in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of <money>US$35.54 million</money> and an adjusted net profit (non-IFRS measure) of <money>US$51.23 million</money>, with positive operating cash flow. The Company's total cash http://www.streetinsider.com/PRNewswire/Commercialization+Roadmap+Validated+with+Three-digit+Million-dollar+Revenue%3A+Insilico+Medicine+Announces+Interim+Results+for+the+First+Half+of+2026/26976985.html Wed, 26 Aug 2026 06:37:00 -0400 3696 A.06822034 A.11003533 A.20111752 A.38554088 A.50216935 O.15116613 O.20026344 O.24152401 O.42313267 O.57690994 O15 http://www.streetinsider.com/Management+Changes/Longeveron+names+Nirav+Jhaveri+as+CFO/26950025.html <p>Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.</p> <p>Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.</p> <p>Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held http://www.streetinsider.com/Management+Changes/Longeveron+names+Nirav+Jhaveri+as+CFO/26950025.html Wed, 19 Aug 2026 16:05:16 -0400 3696 A.50216935 DERM IRD LGVN LGVNR O.01227350 O.26057861 O.49866458 O.57690994 O15